



**Washington State Health Care Authority
Prescription Drug Program**

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

March 8, 2023

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (WA PDL), effective April 1, 2023 for UMP and effective July 1, 2023 for L&I:

Antidepressants – Other reviewed 10/19/2022		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
bupropion HCL	bupropion HCL tablet	Yes	Yes
	bupropion HCL ER tablet	Yes	Yes
	bupropion HCL SR tablet	Yes	Yes
	bupropion HCL XL tablet	Yes	Yes
mirtazapine	mirtazapine tablet	Yes	Yes
	mirtazapine ODT tablet dispersible	Yes	Yes
The effect of this recommendation is no change to the PDL.			
Antidepressants – SNRI		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
desvenlafaxine	desvenlafaxine ER tablet	Yes	Yes
duloxetine HCL	duloxetine HCL capsule	Yes	Yes
venlafaxine HCL	venlafaxine HCL tablet	Yes	Yes
	venlafaxine HCL ER capsule	Yes	Yes
The effect of this recommendation is to make desvenlafaxine ER preferred on the WA PDL.			
Antidepressants – SSRI		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
citalopram HBR	citalopram HBR tablet	Yes	Yes
escitalopram oxalate	escitalopram oxalate tablet	Yes	Yes
fluoxetine HCL	fluoxetine HCL capsule	Yes	Yes
	fluoxetine HCL solution	Yes	Yes
fluvoxamine maleate	fluvoxamine maleate tablet	Yes	Yes
paroxetine HCL	paroxetine HCL tablet	Yes	Yes
sertraline HCL	sertraline HCL tablet	Yes	Yes
vilazodone HCL	vilazodone HCL tablet	Yes	Yes
The effect of this recommendation is to make Fluoxetine DR non-preferred on the WA PDL and to make vilazodone HCL preferred on the WA PDL.			

ADHD – Amphetamines reviewed 02/16/2022		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP

mixed amphetamine salts	amphetamine/ dextroamphetamine 24hr capsule	Not participating	Yes
	amphetamine/ dextroamphetamine tablet		Yes
dextroamphetamine sulfate	dextroamphetamine sulfate tablet		Yes
	dextroamphetamine sulfate ER capsule		Yes
lisdexamfetamine dimesylate	Vyvanse [®] capsule		Yes
	Vyvanse [®] chewable	Yes	
The effect of this recommendation is no change to the WA PDL.			
ADHD – Methylphenidates			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dexmethylphenidate HCL	dexmethylphenidate HCL tablet	Not participating	Yes
	dexmethylphenidate HCL ER capsule		Yes
methylphenidate HCL	methylphenidate HCL tablet, solution, chewable		Yes
	methylphenidate HCL ER tablet, capsule		Yes
	methylphenidate HCL LA capsule		Yes
	methylphenidate HCL CD capsule	Yes	
The effect of this recommendation is no change to the WA PDL.			
ADHD – Non-Stimulant			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
atomoxetine HCL	atomoxetine HCL capsule	Not participating	Yes
clonidine HCL	clonidine HCL tablet, pack		Yes
	clonidine HCL ER tablet		Yes
guanfacine HCL	guanfacine tablet		Yes
	guanfacine ER tablet		Yes
The effect of this recommendation is no change to the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,



Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority